Abbott India Limited Logo

Abbott India Limited

ABBOTINDIA.NS

(3.2)
Stock Price

27.336,05 INR

23.89% ROA

37.82% ROE

48.97x PER

Market Cap.

606.694.076.625,00 INR

2.25% DER

1.44% Yield

20.9% NPM

Abbott India Limited Stock Analysis

Abbott India Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Abbott India Limited Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (70.07%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

With a remarkably low PBV ratio (0x), the stock offers substantial upside potential at a bargain price.

3 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Revenue Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

5 Net Profit Growth

Over the last five years, this company's net profit has shown continuous growth, reflecting a robust financial performance and making it an attractive choice for potential investors.

6 Dividend

With a solid track record of dividend payments over the past five years, the company has established itself as a dependable choice for investors seeking consistent income.

7 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (149.316), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

8 ROA

The stock's ROA (0%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

9 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

10 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

11 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

Abbott India Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Abbott India Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Abbott India Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Abbott India Limited Revenue
Year Revenue Growth
2004 4.050.700.000
2005 4.446.700.000 8.91%
2006 5.102.400.000 12.85%
2007 5.943.200.000 14.15%
2008 6.657.000.000 10.72%
2009 7.609.264.000 12.51%
2010 9.898.808.000 23.13%
2011 14.455.729.000 31.52%
2012 16.097.738.000 10.2%
2013 18.693.835.000 13.89%
2014 22.351.156.000 16.36%
2015 25.782.995.000 13.31%
2016 28.859.332.000 10.66%
2017 33.004.748.000 12.56%
2018 36.755.338.000 10.2%
2019 40.911.815.000 10.16%
2020 43.081.400.000 5.04%
2021 49.103.000.000 12.26%
2022 53.487.300.000 8.2%
2023 59.765.600.000 10.5%
2023 58.489.100.000 -2.18%
2024 62.304.400.000 6.12%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Abbott India Limited Research and Development Expenses
Year Research and Development Expenses Growth
2004 0
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 7.059.000 100%
2016 7.573.000 6.79%
2017 687.100 -1002.17%
2018 6.727.000 89.79%
2019 6.900.000 2.51%
2020 8.400.000 17.86%
2021 8.100.000 -3.7%
2022 7.900.000 -2.53%
2023 0 0%
2023 9.600.000 100%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Abbott India Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2004 203.000.000
2005 195.000.000 -4.1%
2006 223.300.000 12.67%
2007 290.300.000 23.08%
2008 385.700.000 24.73%
2009 420.562.000 8.29%
2010 145.798.000 -188.46%
2011 874.302.000 83.32%
2012 312.831.000 -179.48%
2013 622.881.000 49.78%
2014 498.998.000 -24.83%
2015 720.356.000 30.73%
2016 800.875.000 10.05%
2017 757.873.000 -5.67%
2018 890.989.000 14.94%
2019 814.586.000 -9.38%
2020 1.342.200.000 39.31%
2021 1.584.000.000 15.27%
2022 1.316.700.000 -20.3%
2023 0 0%
2023 4.844.800.000 100%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Abbott India Limited EBITDA
Year EBITDA Growth
2004 1.425.300.000
2005 911.400.000 -56.39%
2006 919.500.000 0.88%
2007 1.054.600.000 12.81%
2008 1.014.400.000 -3.96%
2009 1.268.166.000 20.01%
2010 1.066.431.000 -18.92%
2011 1.993.547.000 46.51%
2012 2.082.338.000 4.26%
2013 2.318.655.600 10.19%
2014 3.597.872.000 35.55%
2015 4.168.220.000 13.68%
2016 4.538.697.000 8.16%
2017 5.970.775.000 23.98%
2018 7.074.174.000 15.6%
2019 8.710.292.000 18.78%
2020 10.074.600.000 13.54%
2021 11.656.000.000 13.57%
2022 13.597.800.000 14.28%
2023 17.455.600.000 22.1%
2023 14.531.000.000 -20.13%
2024 15.640.400.000 7.09%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Abbott India Limited Gross Profit
Year Gross Profit Growth
2004 1.560.600.000
2005 1.489.100.000 -4.8%
2006 1.569.100.000 5.1%
2007 1.858.400.000 15.57%
2008 2.110.900.000 11.96%
2009 2.567.705.000 17.79%
2010 3.425.734.000 25.05%
2011 5.866.794.000 41.61%
2012 6.381.251.000 8.06%
2013 7.818.216.000 18.38%
2014 9.231.511.000 15.31%
2015 10.702.233.000 13.74%
2016 11.738.679.000 8.83%
2017 13.957.304.000 15.9%
2018 15.869.381.000 12.05%
2019 17.755.297.000 10.62%
2020 19.172.200.000 7.39%
2021 22.530.900.000 14.91%
2022 23.736.700.000 5.08%
2023 27.191.600.000 12.71%
2023 19.805.500.000 -37.29%
2024 21.272.800.000 6.9%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Abbott India Limited Net Profit
Year Net Profit Growth
2004 1.022.500.000
2005 591.700.000 -72.81%
2006 598.600.000 1.15%
2007 684.300.000 12.52%
2008 628.700.000 -8.84%
2009 775.102.000 18.89%
2010 609.352.000 -27.2%
2011 1.203.930.000 49.39%
2012 1.447.005.000 16.8%
2013 1.667.507.000 13.22%
2014 2.289.593.000 27.17%
2015 2.596.277.000 11.81%
2016 2.766.488.000 6.15%
2017 4.012.178.000 31.05%
2018 4.503.318.000 10.91%
2019 5.929.300.000 24.05%
2020 6.906.900.000 14.15%
2021 7.987.000.000 13.52%
2022 9.494.100.000 15.87%
2023 12.517.600.000 24.15%
2023 12.012.200.000 -4.21%
2024 13.120.400.000 8.45%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Abbott India Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2004 67
2005 39 -73.68%
2006 39 2.56%
2007 46 15.22%
2008 44 -6.98%
2009 57 23.21%
2010 45 -27.27%
2011 57 21.43%
2012 68 17.65%
2013 78 12.82%
2014 108 27.1%
2015 120 10.83%
2016 130 7.69%
2017 189 30.85%
2018 212 10.9%
2019 279 24.37%
2020 325 14.15%
2021 376 13.33%
2022 447 15.92%
2023 589 24.28%
2023 565 -4.25%
2024 617 8.43%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Abbott India Limited Free Cashflow
Year Free Cashflow Growth
2004 637.800.000
2005 338.000.000 -88.7%
2006 359.500.000 5.98%
2007 196.000.000 -83.42%
2008 650.200.000 69.86%
2009 292.323.000 -122.43%
2010 339.286.000 13.84%
2011 85.615.000 -296.29%
2012 840.855.000 89.82%
2013 1.098.093.600 23.43%
2014 1.967.138.000 44.18%
2015 2.259.521.000 12.94%
2016 2.857.136.000 20.92%
2017 1.284.413.000 -122.45%
2018 4.866.413.000 73.61%
2019 6.103.781.000 20.27%
2020 7.034.300.000 13.23%
2021 9.035.900.000 22.15%
2022 8.592.800.000 -5.16%
2023 13.079.100.000 34.3%
2023 0 0%
2024 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Abbott India Limited Operating Cashflow
Year Operating Cashflow Growth
2004 683.700.000
2005 368.200.000 -85.69%
2006 407.400.000 9.62%
2007 305.400.000 -33.4%
2008 865.100.000 64.7%
2009 371.574.000 -132.82%
2010 460.638.000 19.33%
2011 240.659.000 -91.41%
2012 1.013.492.000 76.25%
2013 1.242.511.200 18.43%
2014 2.147.766.000 42.15%
2015 2.514.324.000 14.58%
2016 3.072.193.000 18.16%
2017 1.527.037.000 -101.19%
2018 4.991.307.000 69.41%
2019 6.261.091.000 20.28%
2020 7.267.400.000 13.85%
2021 9.476.600.000 23.31%
2022 8.933.900.000 -6.07%
2023 13.562.400.000 34.13%
2023 0 0%
2024 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Abbott India Limited Capital Expenditure
Year Capital Expenditure Growth
2004 45.900.000
2005 30.200.000 -51.99%
2006 47.900.000 36.95%
2007 109.400.000 56.22%
2008 214.900.000 49.09%
2009 79.251.000 -171.16%
2010 121.352.000 34.69%
2011 155.044.000 21.73%
2012 172.637.000 10.19%
2013 144.417.600 -19.54%
2014 180.628.000 20.05%
2015 254.803.000 29.11%
2016 215.057.000 -18.48%
2017 242.624.000 11.36%
2018 124.894.000 -94.26%
2019 157.310.000 20.61%
2020 233.100.000 32.51%
2021 440.700.000 47.11%
2022 341.100.000 -29.2%
2023 483.300.000 29.42%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Abbott India Limited Equity
Year Equity Growth
2004 1.882.800.000
2005 2.164.400.000 13.01%
2006 2.458.100.000 11.95%
2007 2.310.200.000 -6.4%
2008 2.212.500.000 -4.42%
2009 2.715.562.000 18.53%
2010 3.053.823.000 11.08%
2011 5.441.426.000 43.88%
2012 6.468.591.000 15.88%
2013 7.878.513.000 17.9%
2014 9.375.276.000 15.97%
2015 11.076.422.000 15.36%
2016 13.869.440.000 20.14%
2017 16.927.595.000 18.07%
2018 20.085.852.000 15.72%
2019 24.317.073.000 17.4%
2020 26.021.600.000 6.55%
2021 28.197.900.000 7.72%
2022 31.885.400.000 11.56%
2023 36.988.900.000 13.8%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Abbott India Limited Assets
Year Assets Growth
2004 3.121.100.000
2005 3.103.700.000 -0.56%
2006 3.405.000.000 8.85%
2007 3.303.800.000 -3.06%
2008 3.505.500.000 5.75%
2009 3.829.145.000 8.45%
2010 4.534.320.000 15.55%
2011 8.002.496.000 43.34%
2012 9.071.108.000 11.78%
2013 11.391.910.000 20.37%
2014 13.736.310.000 17.07%
2015 16.240.692.000 15.42%
2016 20.638.082.000 21.31%
2017 24.161.891.000 14.58%
2018 29.409.116.000 17.84%
2019 35.468.486.000 17.08%
2020 38.404.500.000 7.64%
2021 42.241.200.000 9.08%
2022 45.555.100.000 7.27%
2023 51.934.900.000 12.28%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Abbott India Limited Liabilities
Year Liabilities Growth
2004 1.238.300.000
2005 939.300.000 -31.83%
2006 946.900.000 0.8%
2007 993.600.000 4.7%
2008 1.293.000.000 23.16%
2009 1.113.583.000 -16.11%
2010 1.480.497.000 24.78%
2011 2.561.070.000 42.19%
2012 2.602.517.000 1.59%
2013 3.061.294.000 14.99%
2014 4.361.034.000 29.8%
2015 5.164.270.000 15.55%
2016 6.768.642.000 23.7%
2017 7.234.296.000 6.44%
2018 9.323.264.000 22.41%
2019 11.151.413.000 16.39%
2020 12.382.900.000 9.95%
2021 14.043.300.000 11.82%
2022 13.669.700.000 -2.73%
2023 14.946.000.000 8.54%

Abbott India Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
2789.51
Net Income per Share
583.07
Price to Earning Ratio
48.97x
Price To Sales Ratio
10.24x
POCF Ratio
84.31
PFCF Ratio
88.46
Price to Book Ratio
16.4
EV to Sales
9.89
EV Over EBITDA
36.63
EV to Operating CashFlow
81.46
EV to FreeCashFlow
85.47
Earnings Yield
0.02
FreeCashFlow Yield
0.01
Market Cap
606,69 Bil.
Enterprise Value
586,18 Bil.
Graham Number
4778.77
Graham NetNet
1471.26

Income Statement Metrics

Net Income per Share
583.07
Income Quality
0.58
ROE
0.38
Return On Assets
0.24
Return On Capital Employed
0.4
Net Income per EBT
0.74
EBT Per Ebit
1.09
Ebit per Revenue
0.26
Effective Tax Rate
0.26

Margins

Sales, General, & Administrative to Revenue
0.01
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.39
Operating Profit Margin
0.26
Pretax Profit Margin
0.28
Net Profit Margin
0.21

Dividends

Dividend Yield
0.01
Dividend Yield %
1.44
Payout Ratio
0
Dividend Per Share
410

Operating Metrics

Operating Cashflow per Share
338.63
Free CashFlow per Share
322.76
Capex to Operating CashFlow
0.05
Capex to Revenue
0.01
Capex to Depreciation
0.64
Return on Invested Capital
0.3
Return on Tangible Assets
0.24
Days Sales Outstanding
19.65
Days Payables Outstanding
102.05
Days of Inventory on Hand
63.06
Receivables Turnover
18.58
Payables Turnover
3.58
Inventory Turnover
5.79
Capex per Share
15.87

Balance Sheet

Cash per Share
1.916,20
Book Value per Share
1.740,71
Tangible Book Value per Share
1737.58
Shareholders Equity per Share
1740.71
Interest Debt per Share
44.75
Debt to Equity
0.02
Debt to Assets
0.02
Net Debt to EBITDA
-1.28
Current Ratio
2.42
Tangible Asset Value
36,92 Bil.
Net Current Asset Value
17,51 Bil.
Invested Capital
21381700000
Working Capital
19,03 Bil.
Intangibles to Total Assets
0
Average Receivables
1,60 Bil.
Average Payables
5,01 Bil.
Average Inventory
3097900000
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Abbott India Limited Dividends
Year Dividends Growth
2008 18
2009 14 -21.43%
2010 17 17.65%
2011 17 0%
2012 17 0%
2013 17 0%
2014 23 26.09%
2015 31 25.81%
2016 35 11.43%
2017 40 12.5%
2018 5 -700%
2019 15 66.67%
2020 143 89.51%
2021 155 7.74%
2022 130 -19.23%
2023 145 10.34%
2024 410 64.63%

Abbott India Limited Profile

About Abbott India Limited

Abbott India Limited operates as a pharmaceutical company in India. It offers pharmaceutical products for various therapeutic areas, such as women's health, gastroenterology, metabolic, central nervous system, pain management, pre-term labor, vitamins, insomnia, vaccines, consumer health, etc. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. Abbott India Limited was incorporated in 1944 and is headquartered in Mumbai, India. Abbott India Limited is a subsidiary of Abbott Capital India Limited.

CEO
Mr. Sridhar Kadangode
Employee
3.814
Address
Godrej BKC
Mumbai, 400051

Abbott India Limited Executives & BODs

Abbott India Limited Executives & BODs
# Name Age
1 Ms. Sangeeta Mukesh Shetty
Company Secretary & Compliance Officer
70
2 Ms. Swati Dalal
MD & Director
70
3 Mr. Sridhar Kadangode
Chief Financial Officer
70
4 Mr. Rajan Kalantre
Director of Business Human Resources
70

Abbott India Limited Competitors

Sanofi India Limited Logo
Sanofi India Limited

SANOFI.NS

(2.2)
Dr. Lal PathLabs Limited Logo
Dr. Lal PathLabs Limited

LALPATHLAB.NS

(2.8)
Nestlé India Limited Logo
Nestlé India Limited

NESTLEIND.NS

(3.8)